Ofatumumab

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Do not take if: Active HBV infection.
History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA. Hypersensitivity reactions have included anaphylaxis and angioedema.

Side effects, and when to stop

The following clinically significant adverse reactions are discussed in greater detail elsewhere in the labeling:

Infections
Injection-Related Reactions and Hypersensitivity Reactions
Reduction in Immunoglobulins
Liver Injury

Who should not take it

KESIMPTA is contraindicated in patients with:

Active HBV infection.
History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA. Hypersensitivity reactions have included anaphylaxis and angioedema.

Storing it

KESIMPTA Sensoready pens and prefilled syringes must be refrigerated at 2ºC to 8ºC (36ºF to 46ºF). Keep the product in the original carton to protect from light until the time of use. Do not freeze. To avoid foaming, do not shake.

If necessary, KESIMPTA may be stored for up to 7 days at room temperature, not to exceed 30°C (86°F). Write the date removed from the refrigerator in the space provided on the carton labeling. If stored below 30°C (86°F), unused KESIMPTA may be returned to the refrigerator and must be used within the next 7 days or discarded after 7 days.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Ofatumumab; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/ofatumumab
APA 7th: sofidex. (2026, August 3). Ofatumumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/ofatumumab
AMA 11th: Ofatumumab. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/ofatumumab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.